New Stock News | Jingze Biotech's Hong Kong Stock IPO Prospectus Invalid

Jingze Biomedical (Hefei) Co., Ltd. (referred to as "Jingze Biomedical") submitted its Hong Kong stock prospectus on June 27, which expired after 6 months on December 27. At the time of submission, CICC and Guoyuan International were its joint sponsors. According to the previously disclosed prospectus, Jingze Biomedical is a biopharmaceutical company focused on two high-growth tracks of assisted reproductive drugs and ophthalmic drugs. Guided by unmet clinical needs, the company has established a comprehensive research and development system and commercial-scale production capacity. With its systemic capabilities, the company independently developed multiple product pipelines and has advanced many high-tech barrier drugs with great commercial prospects to late-stage clinical trials and commercialization.